Slide 1: Results Presentation 2015 Financial Year
Vita Life Sciences Ltd Results Presentation 2015 Financial Year herbsofgold’ taScience Vital | [ Enriching Lives .Since 1947 /| 19 February 2016
Slide 2: Asia Pacific pharmaceutical and healthcare over-the-counter business
Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements 750 - 800 registered sku of vitamins and supplements sold in 7 countries in the Asia Pacific region 3 major brands VitaHealth: produ
Slide 3: 8th consecutive year of sales growth
1 8th consecutive year of sales growth culminated in revenue of $38.6m. Up 5.5% over FY14 Group operating performance: Australia strong, Singapore steady and Malaysia rebounded 2 in 2nd half 3 2015 EBIT $6.1m, down 11.4% on FY14 due to: • Soft 1st half; 2nd half EBIT of $3.7m increased 4.3% over H2’
Slide 4: Senior management and market rollout
1 Senior management: Second step implemented in positioning VSC for next stage of lifecycle and growth with the appointment of CEO for Malaysia and Singapore 2 Australia: • International distribution arrangements for Herbs of Gold secured with sales expectations being achieved • Rollout of Vita Scie
Slide 5: Revenue, EBIT, DPS
Revenue EBIT DPS (A$m) (A$m) (cps) 40 8 4 35 30 6 3 H2 H2 H2 H2 25 H2 H2 20 4 2 15 10 2 1 H1 H1 H1 H1 H1 5 H1 0 0 0 2014 2015 2014 2015 2014 2015 4
Slide 6: Revenue by geography 2014 and 2015
2014 revenue by geography 2015 revenue by geography Other Asia Other Asia Australia Australia 38% 6% 41% 9% Singapore Singapore 15% 16% Asia Asia 62% 59% Malaysia Malaysia OTC OTC 37% 38% Total revenue: $36.6m Total revenue: $38.6m 5
Slide 7: Management’s strategy delivered record sales
Management’s strategy delivered record sales of $15.6m, a 13.7% increase against FY14 EBIT of $3.1m was up 18.8% against FY14 Strategy remains to differentiate unique premium ingredient formulation products within the ‘Herbs of Gold’ and ‘Vita Science’ brands and exclusively supply health food
Slide 8: Regained momentum in H2 with solid full year result
Regained momentum in H2 with solid full year result Malaysian revenue of $14.4m was a record and at a time where economic and trading conditions were difficult EBIT rebounded in H2 to $1.3m • 4.4% increase over H2’2014 of $1.2m • 92.2% increase over H1’2015 of $0.6m New CEO to continue to bu
Slide 9: Reinvigorated sales and marketing effort
Reinvigorated sales and marketing effort led to revenue increasing to $6.3m, up 10.6% on FY14 The introduction of the Herbs of Gold brand into the Singaporean market during 2015 aided sales EBIT of $2.1m decreased marginally (1.8%) against FY14 as a result of strong competition Revenue (A$m) E
Slide 10: Revenue decreased by 32.3% to $2.3m
(1) Revenue decreased by 32.3% to $2.3m as a result of: • The planned introduction of a new management team in Thailand • The reduced number of products able to be sold in China (industry wide new regulatory regime impacting OTC products) EBIT losses widened to $1.0m in 2015 (2014: $0.5m) a dire
Slide 11: Directors increased the final dividend
Directors increased the final dividend to 2.25 cents per share for FY15. Dividends paid to shareholders for FY15 total 3.75 cents per share Final dividend is unfranked and fully sourced from Foreign Conduit Income Strong operating cashflow conversion combined with prudent financial management
Slide 12: Build out the ‘Vita Sciences’ brand
The Board continues to actively explore strategies to capitalise on the established platform in Australia, Malaysia and Singapore and develop its business in Thailand, China, Vietnam and Indonesia Two key growth strategies implemented in mature markets: • Build out the ‘Vita Sciences’ brand with
Slide 13: The Company’s steady growth in recent years
The Company’s steady growth in recent years is expected to continue in 2016 Given the Company’s diverse operating platform the Directors intend to provide more detailed guidance mid way through the year 12
Slide 14: Appendix
Appendix
Slide 15: Income statement summary
Year ended 31 December 2015 2014 Change $m $m % Revenue 38.6 36.6 5.5% EBITDA 6.2 7.0 -11.4% EBIT 6.1 6.9 -11.4% Profit before tax 6.0 6.9 -13.3% Profit after tax (1) 4.4 7.3 -39.7% EPS (Diluted – cents) 7.7 12.8 -39.8% Dividend (cents / share) 3.75 3.50 7.1% (1) Profit After Tax in 2014 includes th
Slide 16: Balance Sheet as at 31 December
Balance Sheet as at 31 December 2015 2014 $m $m Current assets 23.5 20.8 Non-current assets 8.9 9.5 Total Assets 32.4 30.3 Current liabilities (6.9) (5.5) Non-current liabilities (2.6) (3.2) Total Liabilities (9.5) (8.7) Net Assets 22.9 21.6 15
Slide 17: Cash Flow
Cash Flow 2015 2014 $m $m Receipts from customers 42.3 38.9 Payments to suppliers and employees (36.6) (31.9) Gross operating cash flow 5.7 7.0 EBITDA 6.2 7.0 Gross operating cash flow / EBITDA 93% 100% Net interest received 0.0 0.1 Income tax paid (0.8) (1.0) Operating cash flows 4.9 6.1 Net invest
Slide 18: Disclaimer
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis
Slide 19: Contact Details
Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 18